Sign in

You're signed outSign in or to get full access.

CC

Cytosorbents Corp (CTSO)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 revenue declined 3% YoY to $8.73M, gross margin held at 71%, and operating loss improved 17% YoY; GAAP net loss narrowed sharply to $1.48M ($0.02/share) helped by FX, while adjusted EBITDA loss improved to $2.7M .
  • Against S&P Global consensus, CTSO missed revenue ($8.73M vs $9.01M*) but beat EPS (−$0.02 vs −$0.07*)—a mixed print that still shows operating leverage from lower OpEx and manufacturing cost controls (−11% production costs YoY) * .
  • Management reiterated H2 2025 inflection goals: return Germany (≈40% of sales) to growth post sales reorg, expand gross margins as production normalizes, and drive the core business toward near breakeven in H2 2025 .
  • Regulatory path is the key stock catalyst: FDA denied the DrugSorb-ATR De Novo on Apr 25; company met with FDA and later filed a supervisory appeal on Jun 18 with an expected ~60-day decision timeline and still targets final U.S./Canada decisions in 2025 .
  • Liquidity strengthened by an oversubscribed rights offering and Series A warrant exercises, unlocking $5M restricted cash and adding net liquidity of ~$11.8M; Q1 cash, cash equivalents and restricted cash rose to $13.11M .

What Went Well and What Went Wrong

What Went Well

  • EPS beat versus consensus on tight cost control: GAAP EPS was −$0.02 vs −$0.07 consensus*, with adjusted net loss holding steady YoY at $3.7M and adjusted EBITDA loss improving 17% YoY to $2.7M *.
  • Non-Germany execution offset disruption: “Strong revenue growth in our distributor and other direct sales territories across the E.U. helped to substantially offset a temporary disruption in direct sales in Germany,” per CEO .
  • Gross margin resilience and cost actions: Product gross margin held at 71% (vs 77% LY), with CFO citing a 23% YoY reduction in units produced and 11% reduction in production costs; volumes are expected to increase through 2025 .

What Went Wrong

  • Revenue miss: Product revenue of $8.73M missed S&P Global consensus of $9.01M*, reflecting the anticipated Germany disruption from the sales force realignment * .
  • Germany softness: Germany (≈40% of sales) was a headwind during the reorg; management aims to reaccelerate in H2 2025, but near-term drag persisted in Q1 .
  • FDA setback for DrugSorb-ATR: FDA denial of the De Novo in April raised regulatory risk; management is pursuing appeal/senior engagement to resolve remaining issues in 2025 .

Financial Results

Quarterly actuals (oldest → newest)

MetricQ3 2024Q4 2024Q1 2025
Product Revenue ($)$8,612,795 $9,150,416 $8,727,238
Gross Margin %61% 71% 71%
Operating Loss ($)$(4,396,247) $(3,729,107) $(3,887,205)
Net Loss ($)$(2,334,091) $(7,567,613) $(1,478,355)
Diluted EPS ($)$(0.04) $(0.14) $(0.02)
Adjusted EBITDA ($)$(3,557,000) $(2,420,000) $(2,700,000)
Cash, Cash Equivalents & Restricted Cash (period-end, $)$12.2M $9.8M $13,109,733

Q1 2025 vs S&P Global consensus

MetricActual (Q1 2025)Consensus (Q1 2025)# of Estimates
Product Revenue ($)$8,727,238 $9,007,330*3*
Diluted EPS ($)$(0.02) $(0.07)*3*

Values with * are retrieved from S&P Global.

KPIs and operating drivers

  • Unit production change YoY: −23% (Q1)
  • Production cost change YoY: −11% (Q1)
  • Operating expenses: $10.09M (−12% YoY)
  • Germany share of sales: ≈40% (strategic focus area)
  • Adjusted net loss per share: $(0.06)
  • Liquidity actions: Rights offering net proceeds $6.8M and release of $5.0M restricted cash; total cash, cash equivalents & restricted cash $13.11M at 3/31/25

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Germany sales trajectory1H/2H 2025Expected short-term disruption in Q1 due to German salesforce realignment; aim to improve in H2 2025 Disruption observed in Q1; targeting return to growth in H2 2025 with reorganized team Maintained
Core business profitability2H 2025Manage core business toward breakeven in 2025 “Approaching cash flow breakeven in the second half of the year” Maintained/clarified timing
Gross margin2025Normalize after Q3 2024 production issues Expect expansion in 2025 as volumes increase and ops smooth Raised qualitatively
Production volumes2025Ramp from Q4 normalization Expect volumes to increase across the year Maintained
DrugSorb-ATR (U.S.)2025FDA/HC decisions expected in 2025 FDA De Novo denied Apr 25; appeal filed Jun 18; ~60-day appeal decision timeline; still expect 2025 decision Path updated; timeline reaffirmed
DrugSorb-ATR (Canada)2025Advanced review; decision expected 2025 Advanced review; decision expected 2025 (backlog at Health Canada) Maintained
Capital access2025Pro forma liquidity improved post offering $5M second loan tranche available upon FDA approval, potentially 2H 2025 New detail

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q4 2024)Current Period (Q1 2025)Trend
Germany sales & executionQ3: solid execution outside Germany; margins dipped with production slowdown . Q4: sales reorg in Germany; warned of Q1 softness, H2 improvement targeted .Disruption in Germany as anticipated; target H2 return to growth; positive early Q2 signs .Improving from Q2; H2 inflection targeted
Gross margin/manufacturingQ3: margin 61% due to planned slowdown; normalization expected Q4 . Q4: margin 71% .Margin 71%; units −23% YoY with −11% production costs; volumes to rise in 2025 .Stable-to-up with volume
Regulatory (DrugSorb-ATR)Q3: FDA De Novo accepted; HC MDL submitted . Q4: decisions expected 2025 .FDA De Novo denial (Apr 25); pursuing formal appeal; aiming for 2025 U.S./Canada decisions .Mixed: setback, but active appeal
Liquidity/capitalQ3: cash incl. restricted $12.2M . Q4: rights offering boosts pro forma liquidity .Q1 cash+restricted $13.11M; unlocked $5M restricted cash; $6.8M net proceeds; additional $1.7M NJ credits .Strengthened
Regional expansionN/AOpened Dubai subsidiary to drive MEA growth .Expanding
Clinical/reimbursementGrowing data; registry presentations forthcoming .Continued real-world data; leveraging for EU reimbursement; clean safety profile noted .Building evidence base

Management Commentary

  • “Strong revenue growth in our distributor and other direct sales territories across the E.U. helped to substantially offset a temporary disruption in direct sales in Germany… [reorganization] intended to renew sales growth… through deeper customer engagement, more effective market development, and improved sales representative productivity.” — CEO .
  • “Gross margin… 71%… lower than 76% in Q1 2024. The year-over-year decrease was primarily due to a 23% reduction in the number of units produced… partially offset by an 11% reduction in production costs.” — CFO .
  • “We believe our actions will drive improved execution and results in the second half of the year… approaching cash flow breakeven in the second half of the year.” — CFO .
  • “We believe that our submission package and data are strong… most direct path forward is the filing of a formal appeal… estimated approximately 60 days after the filing date.” — CMO .
  • “Germany… accounts for approximately 40% of our sales… reorganization and new efforts… started at the beginning of the first quarter… we’ll see benefits in the second half of this year.” — CEO .

Q&A Highlights

  • FDA appeal pathway and confidence: Management views the appeal as the most expedient route, believes existing data are sufficient, and noted no FDA request for an additional trial at this time .
  • EU reimbursement leverage: Company plans to use expanding registry/clinical data to support reimbursement decisions across Europe (beyond Germany) .
  • Germany reacceleration visibility: Management cited controllable execution levers (salesforce optimization, medical messaging) and early Q2 promise toward H2 growth resumption .

Estimates Context

  • Q1 2025 revenue missed S&P Global consensus ($8.73M actual vs $9.01M estimate; 3 estimates)* while EPS beat (−$0.02 actual vs −$0.07 estimate; 3 estimates)* *.
  • Sequentially, revenue declined 4.6% from Q4 ($9.15M) to Q1 ($8.73M) as guided; product gross margin stayed at 71% in both periods .
    Values with * are retrieved from S&P Global.

Key Takeaways for Investors

  • Near-term setup: Mixed print (rev miss, EPS beat) with line-of-sight to H2 improvements as Germany reorganization benefits flow through and production volumes rise—monitor Q2 trajectory and margin cadence .
  • Regulatory catalyst path: The FDA appeal (filed Jun 18) creates a defined timeline (~60 days from filing) for a key binary; management continues to expect 2025 U.S./Canada decisions—stock likely sensitive to these updates .
  • Operating leverage: Sustained OpEx discipline (−12% YoY), improved adjusted EBITDA, and stable 71% product margins support the H2 breakeven objective if top-line reaccelerates .
  • Liquidity de-risking: Rights offering/warrant exercises unlocked cash and added liquidity (~$11.8M), with an additional $5M debt tranche contingent on FDA approval—reduces financing overhang into 2025 milestones .
  • Execution focus: Germany (≈40% of sales) is the fulcrum—evidence of order momentum and productivity gains in Q2/Q3 would validate reorg; Dubai subsidiary adds optionality in MEA .
  • Data flywheel: Ongoing registry/publication flow underpins clinical value and EU reimbursement efforts, supporting adoption irrespective of U.S. timelines .
  • Risk balance: Regulatory outcomes and Germany recovery drive variance; consensus likely revisits revenue pacing and margin expectations given Q1 miss and H2 targets *.

Other Relevant Press Releases (Q1–Q2 timing for context)

  • Rights Offering closed, oversubscribed; unlocked $5.0M restricted cash; pro forma liquidity improved .
  • Series A Warrant exercises added $1.6M gross proceeds; total gross proceeds $7.85M; ~4.8M shares reserved for Series B warrants (expired Apr 10) .
  • Dubai regional subsidiary opened to accelerate MEA expansion .
  • DrugSorb-ATR regulatory update: FDA denial (Apr 25); ongoing interactions and appeal plan; targeting 2025 decision .